BSECompany Update6d ago · 30 Jul 2026, 12:58 pm
Earnings Conference call Invite to discuss Un-audited Financial Results of the Company for the Quarter ended 30 June 2026.
Sai Life Sciences Ltd · 544306
✦ AI SummaryResults
Sai Life Sciences Ltd is hosting an earnings conference call on August 7, 2026, to discuss its un-audited financial results for the quarter ended June 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sai Life Sciences Ltd - 544306 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attachments (1)
📄pdf
Download →
8eb125e9-1ce7-4764-8802-9e422a8181e1.pdf
View document text
Date: 30 July 2026
To To
National Stock Exchange of India Limited BSE Limited
Exchange Plaza, C-1, Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Dalal Street
Complex, Bandra (E), Mumbai – 400 051 Mumbai – 400001
NSE Scrip Symbol: SaiLife BSE Scrip Code: 544306
Sub: Intimation of schedule of Earnings conference call.
Dear Sir/ Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, we hereby inform that the Company is hosting the Earnings Conference
call on Friday, 07 August 2026, at 04:00 PM (IST) for discussing Un Audited Financial Results
of the Company for the Quarter ended 30 June 2026.
Complete details of the earnings conference call are attached herewith for your reference.
We request you to take note of the same and oblige.
Thank you.
For Sai Life Sciences Limited
Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721
Encl: As above
Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)
Corporate office Registered office Contact us
T: +91 40 6815 6000,
# L4-01 & 02, SLN Terminus, Survey Plot No. DS-7, IKP Knowledge Park, Turkapally
F: +91 40 6815 6199
#133, Gachibowli Miyapur Road, (V), Shameerpet Mandal, Medchal-Malkajgiri
E: info@sailife.com
Gachibowli, Hyderabad – 500032, (Dist), Hyderabad -500078, Telangana, India.
W: www.sailife.com
Telangana, India.
Sai Life Sciences Q1FY27 Results Conference Call
At 4.00 PM IST on August 7, 2026 (Friday)
We are pleased to invite you to Sai Life Sciences Q1FY27 results conference call with the senior management. The
conference call will be held on Friday, August 7, 2026, at 4:00 PM (IST). The call will be initiated with a brief
management discussion on the earnings performance followed by an interactive Question & Answer session
The details of the earnings call are:
Date: August 7, 2026 | Time Slot (IST): 4:00 PM – 5:00 PM
Dial-in Number: +91 22 6280 1107, +91 22 7115 8008
Other Dial in Numbers:
International Toll Free: USA: 18667462133 | UK: 08081011573 | Singapore: 8001012045 | Hong Kong: 800964448
Pre-Registration Facility for the call and dial in directly without waiting for the operator: Click Here
Or Copy this URL in your browser:
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1777589&linkSecurityString=f0c5443f3
Management Representation from Sai Life Sciences Limited
Mr. Krishna Kanumuri, Managing Director & Chief Executive Officer
Mr. Siva Chittor, Director and Chief Financial Officer
About Sai Life Sciences Limited
Sai Life Sciences is one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO)
that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization
of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions
spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms.
Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards
of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its
capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.
For more information, please visit www.sailife.com
For further information please contact: Investorrelation@sailife.com